摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1H-Pyrrolo[1,2-a]imidazole | 251-75-2

中文名称
——
中文别名
——
英文名称
1H-Pyrrolo[1,2-a]imidazole
英文别名
——
1H-Pyrrolo[1,2-a]imidazole化学式
CAS
251-75-2
化学式
C6H6N2
mdl
MFCD19219229
分子量
106.13
InChiKey
YHZODXGIMHTEJV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    8
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    20.2
  • 氢给体数:
    1
  • 氢受体数:
    0

文献信息

  • Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
    申请人:Wyeth
    公开号:US20040167122A1
    公开(公告)日:2004-08-26
    The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor. 1
    本发明提供了一种I式化合物及其在治疗与5-HT6受体相关或受其影响的疾病中的应用。
  • [EN] OXAZOLIDINONE AND / OR ISOXAZOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS<br/>[FR] DERIVES D'OXAZOLIDINONE ET/OU D'ISOXAZOLINE UTILISES COMME AGENTS ANTIBACTERIENS
    申请人:ASTRAZENECA AB
    公开号:WO2004048392A1
    公开(公告)日:2004-06-10
    A compound of the formula (I), or a pharmaceutically-acceptable salt, or in-vivo hydrolysable ester thereof: formula (I) wherein in (I) C is for example formula (D), formula (E), formula (H) wherein A and B are independently selected from (i) formula (J) and (ii) formula (K) m is 1 or 2; R2b and R6b, R2a and R6a, R3a and R5a, are for example selected from H, F, OMe and Me; R2b' and R6b', R2a' and R6a', R3a', R5a' are for example selected from H, OMe and Me; R1a is for example optionally substituted (1-10C)alkyl; R1b is for example selected from -NR5C(=W)R4, formula (a) , or formula (b) wherein HET-1 is for example isoxazolyl and HET-2 is for example triazolyl or tetrazolyl. Methods for making compounds of the formula (I), compositions containing them and their use as antibacterial agents are also described.
    公式(I)的化合物,或其药用可接受盐,或体内可解酯:公式(I)其中在(I)中,C例如为公式(D),公式(E),公式(H)其中A和B分别选自(i)公式(J)和(ii)公式(K)m为1或2;R2b和R6b,R2a和R6a,R3a和R5a,例如选自H,F,OMe和Me;R2b'和R6b',R2a'和R6a',R3a',R5a'例如选自H,OMe和Me;R1a例如为可选择地取代的(1-10C)烷基;R1b例如选自-NR5C(=W)R4,公式(a),或公式(b)其中HET-1例如为异恶唑基,HET-2例如为三唑基或四唑基。还描述了制备公式(I)的化合物的方法,含有它们的组合物以及它们作为抗菌剂的用途。
  • Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands
    申请人:Elokdah Mahmoud Hassan
    公开号:US20070037802A1
    公开(公告)日:2007-02-15
    The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.
    本发明提供了一种式I化合物及其用于治疗与5-HT6受体相关或受其影响的中枢神经系统疾病的用途。
  • Azinyl-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands
    申请人:Elokdah Mahmoud Hassan
    公开号:US20070054896A1
    公开(公告)日:2007-03-08
    The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.
    本发明提供了一种公式I的化合物,以及该化合物用于治疗与5-HT6受体相关或受其影响的神经中枢系统疾病的用途。
  • Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them
    申请人:Syngenta Limited
    公开号:US20030144263A1
    公开(公告)日:2003-07-31
    Compounds of the formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof, 1 wherein, for example, X is —O— or —S—; HET is an optionally substituted C-linked 5-membered heteroaryl ring containing 2 to 4 heteroatoms independently selected from N, O and S; Q is selected from, for example, Q1 and Q2 2 R 2 and R 3 are independently hydrogen or fluoro; T is selected from a range of groups, for example, an N-linked (fully unsaturated) 5-membered heteroaryl ring system or a group of formula (TC5): 3 wherein Rc is, for example, R 13 CO—, R 13 SO 2 — or R 13 CS—; wherein R 13 is, for example, optionally substituted (1-10C)alkyl or R 14 C(O)O(1-6C)alkyl wherein R 14 is optionally substituted (1-10C)alkyl; are useful as antibacterial agents; and processes for their manufacture and pharmaceutical compositions containing them are described.
    式(I)的化合物,或其药学上可接受的盐,或其体内可解的酯, 其中,例如,X为—O—或—S—; HET是一个可选择的取代的C-连接的含有2到4个异原子(独立选择自N、O和S)的5元杂芳环; Q从Q1和Q2中选择 R2和R3独立地为氢或; T从一系列基团中选择,例如,一个N-连接的(完全不饱和的)5元杂芳环系统或式(TC5)的基团: 其中Rc是,例如,R13CO—,R13SO2—或R13CS—; 其中R13是,例如,可选择的取代的(1-10C)烷基或R14C(O)O(1-6C)烷基 其中R14是可选择的取代的(1-10C)烷基;这些化合物可用作抗菌剂;并描述了其制备方法和含有它们的药物组合物。
查看更多